Y-Linked Pseudogene RBMY2FP as a Prognostic Biomarker and Tumor Suppressor Candidate in Pancreatic Cancer
Gabin Yeun
Newport High School, Bellevue, WA, USA
Publication date: November 20, 2025
Newport High School, Bellevue, WA, USA
Publication date: November 20, 2025
DOI: http://doi.org/10.34614/JIYRC2025II48
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, implicating the need for novel biomarkers and new therapeutic targets. This study evaluated the clinical and functional significance of the Y-linked pseudogene RBMY2FP in PDAC. Kaplan–Meier survival data, a publicly available survival dataset, were analyzed to compare overall survival between high- and low-RBMY2FP expression groups, including an advanced grade (G3–G4) subset. Expression across normal tissues was surveyed, and functional validation was performed by transfecting SNU-324 pancreatic cancer cells with synthetic RBMY2FP mRNA, followed by RT-PCR, fluorescence-based viability counts, and PrestoBlue proliferation assays. Kaplan–Meier survival analysis of 964 patients demonstrated that high RBMY2FP expression was significantly associated with improved overall survival (HR = 0.81, 95% CI: 0.69–0.97, P = 0.0189), with a median survival of 20.17 months compared to 18.0 months in the low-expression cohort. A subgroup analysis of 194 advanced-grade (G3–G4) PDAC patients further revealed a 41% reduction in risk of death for the high-expression group (HR = 0.59, P = 0.00506), with median survival improving from 12.6 to 17.2 months. In vitro, RBMY2FP mRNA transfection significantly increased transcript levels and resulted in a dose-dependent reduction in live cell number and proliferation. These findings nominate RBMY2FP as a prognostic biomarker and tumor-suppressive RNA candidate in PDAC, supporting further mechanistic studies and exploration of RBMY2FP-based RNA therapeutics.
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, implicating the need for novel biomarkers and new therapeutic targets. This study evaluated the clinical and functional significance of the Y-linked pseudogene RBMY2FP in PDAC. Kaplan–Meier survival data, a publicly available survival dataset, were analyzed to compare overall survival between high- and low-RBMY2FP expression groups, including an advanced grade (G3–G4) subset. Expression across normal tissues was surveyed, and functional validation was performed by transfecting SNU-324 pancreatic cancer cells with synthetic RBMY2FP mRNA, followed by RT-PCR, fluorescence-based viability counts, and PrestoBlue proliferation assays. Kaplan–Meier survival analysis of 964 patients demonstrated that high RBMY2FP expression was significantly associated with improved overall survival (HR = 0.81, 95% CI: 0.69–0.97, P = 0.0189), with a median survival of 20.17 months compared to 18.0 months in the low-expression cohort. A subgroup analysis of 194 advanced-grade (G3–G4) PDAC patients further revealed a 41% reduction in risk of death for the high-expression group (HR = 0.59, P = 0.00506), with median survival improving from 12.6 to 17.2 months. In vitro, RBMY2FP mRNA transfection significantly increased transcript levels and resulted in a dose-dependent reduction in live cell number and proliferation. These findings nominate RBMY2FP as a prognostic biomarker and tumor-suppressive RNA candidate in PDAC, supporting further mechanistic studies and exploration of RBMY2FP-based RNA therapeutics.
